Cardium Therapeutics, Inc. Form 8-K August 30, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

DATE OF REPORT (Date of earliest event reported): August 25, 2011

001-33635

(Commission file number)

CARDIUM THERAPEUTICS, INC.

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$

Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

Delaware (State of incorporation) 27-0075787 (IRS Employer

Identification No.)

12255 El Camino Real, Suite 250

San Diego, California 92130 (Address of principal executive offices)

(858) 436-1000 (Registrant s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

ITEM 8.01 OTHER EVENTS.

On August 25, 2011, Cardium Therapeutics, Inc. (Cardium) issued a press release announcing the market introduction of a new Vitamin D supplement, D-Sorb to its MedPodium Healthy Lifestyle Produce line. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Press Release of Cardium issued on August 25, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARDIUM THERAPEUTICS, INC.

Date: August 26, 2011

By: /s/ Christopher J. Reinhard

Christopher J. Reinhard

Chief Executive Officer